Radionuclide therapy.
Nuclear medicine therapy uses unsealed radioactive sources for the selective delivery of radiation to tumours or target organs. For benign disorders such as thyrotoxicosis and arthritis radionuclide therapy provides an alternative to surgery or medical treatment. In cancer treatment, it often combines the advantage of target selectivity (like brachytherapy or external beam radiotherapy) with that of being systemic, as with chemotherapy, and it may be used as part of a therapeutic strategy with curative intent or for disease control and palliation. Toxicity is generally limited to the haematopoietic tissue and few side-effects are observed. When cure is feasible, the long-term consequences of radionuclide therapy (eg, fertility disorders and leukaemia or other secondary cancers) do compare favourably with the risks associated with and accepted for chemotherapy and radiotherapy.
Chatal
J F
JF
Department of Nuclear Medicine, René Gauducheau Cancer Centre, Nantes, France. jfchatal@nantes.inserm.fr
Hoefnagel
C A
CA
D001168:Arthritis / Q000532:radiotherapy; D001918:Brachytherapy; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy; D011868:Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects; D013971:Thyrotoxicosis / Q000532:radiotherapy; D016896:Treatment Outcome
D011868:Radioisotopes